新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 仿制药市场 » 太阳制药同意$40亿收购兰伯西(Ranbaxy)

太阳制药同意$40亿收购兰伯西(Ranbaxy)

来源:生物谷 2014-04-08 01:31

2014年4月7日讯 /生物谷BIOON/ --印度领先的制药公司—太阳制药(Sun Pharmaceutical)4月7日宣布,已同意耗资40亿美元(包括32亿美元股票和8亿美元债务),从日本第一三共制药(Daiichi Sankyo)手中收购陷入困境的印度仿制药生产商兰伯西(Ranbaxy Laboratories)。这将是本年度亚太地区最大的医药板块交易。在印度260亿美元仿制药市场中,Ranbaxy是一家领先的制药公司。此次收购将使Sun Pharma成为印度最大的制药公司,同时将缔造全球第5大仿制药生产商,年收入预计达到42亿美元。

对于日本第4大制药商—第一三共而言,该笔交易标志着一个显著退却,同时突出了印度制药业挥之不去的质量问题。自2008年收购Ranbaxy之后,第一三共在印度的投资已经减半。

此次收购的背景是,FDA出于对Ranbaxy印度工厂生产问题的担忧,已对Ranbaxy进行了数年的制裁,并禁止进口Ranbaxy 2家工厂生产的药品。

此次收购,将使Sun Pharma涉足Ranbaxy强大的全球影响力和制造能力,合并后的公司将拥有47家工厂,遍布五大洲,业务遍及65个国家。目前,该笔交易将同时等待Sun Pharma和Ranbaxy股东的批准。(生物谷Bioon.com)

英文原文:India's Sun Pharma buys Ranbaxy in $4 billion deal

MUMBAI, India (AP) — India's Sun Pharmaceutical Industries is buying troubled generic drugmaker Ranbaxy Laboratories in a $4 billion deal, the companies said Monday.

The combined company will be India's biggest pharmaceutical firm, with annual revenue estimated at $4.2 billion.

Sun Pharma shares rose 1.7 percent. Shares of Ranbaxy, which is 63-percent owned by Japan's Daiichi Sankyo, were down 4.8 percent on the Bombay Stock Exchange.

Ranbaxy is the leading drugmaker in India's $26 billion generic pharmaceutical industry, but it has faced penalties from U.S. regulators for years. The U.S. has banned imports of drugs from two of its factories because of concerns about quality control.

The acquisition will allow Sun Pharma to tap into Ranbaxy's strong global presence and manufacturing capabilities. The combined company will have 47 factories across five continents and operations in 65 countries, said Dilip Shanghvi, Sun Pharma's managing director.

"In high-growth emerging markets, it provides a strong platform which is highly complementary to Sun Pharma's strengths," Shanghvi said. "We see tremendous growth opportunities."

Sun Pharma said the transaction value includes $3.2 billion in stock and nearly $800 million of Ranbaxy debt. Ranbaxy shareholders will receive 0.8 shares of Sun Pharma for each share of Ranbaxy with an implied value of 457 rupees, a premium of 18 percent to Ranbaxy's average share price over 30 days.

Ranbaxy shareholders are expected to own 14 percent of the new company and Ranbaxy's parent company, Daiichi Sankyo, will be the largest single shareholder.

Ranbaxy has annual revenue of about $2 billion.

The acquisition is subject to approval of shareholders of both Sun Pharma and Ranbaxy.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库